Identifying why small cell lung cancer becomes resistant to chemotherapy
Official title: Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer
Funded at Washington University · NIH-10465193 · Data updated 2026-11-12
This study is looking into why small cell lung cancer often doesn't respond to chemotherapy, hoping to find new ways to treat it better for patients who are facing this tough disease.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 1, 2018 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $567,348 |
| NIH project number | 5U01CA231844-05 |
| Project ID | NIH-10465193 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with small cell lung cancer who have experienced a relapse after initial chemotherapy treatment.
✕Less likely to help
Patients with other types of lung cancer or those who have not undergone chemotherapy may not benefit from this research.
What this research studies
This research investigates the mechanisms behind chemotherapy resistance in small cell lung cancer (SCLC), a type of lung cancer with a very low survival rate. By analyzing genetic changes in tumor samples from patients who have relapsed after treatment, the study aims to uncover new therapeutic targets. Additionally, a novel mouse model that mimics human SCLC will be used to test potential treatments and understand how the cancer develops resistance. This approach could lead to more effective therapies for patients suffering from this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments that improve survival rates for patients with small cell lung cancer.
How similar studies have gone: Previous research has shown promise in identifying resistance mechanisms in other cancers, suggesting that this approach could yield valuable insights for small cell lung cancer as well.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Govindan, Ramaswamy — Washington University
- Study coordinator: Govindan, Ramaswamy
Related research
Other NIH-funded projects on the same topics.
-
Stopping chemotherapy from weakening immunotherapy in non-small cell lung cancer
This project looks at whether common chemotherapy makes lung tumors release substances that turn off immune cells and whether blocking that process could help immunotherapy work better for people with non-small cell lung cancer.
-
Understanding how chemotherapy affects immune response in lung cancer treatment
This study is looking at how the chemotherapy drug cisplatin affects the immune system in people with non-small cell lung cancer, to find out how it might make immunotherapy less effective, and to discover better ways to boost treatment options for patients like you.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.